3-(benzyloxy)-1-<<(succinimidyloxy)carbonyl>methyl>-2(1H)-pyridinone | 95215-73-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(benzyloxy)-1-<<(succinimidyloxy)carbonyl>methyl>-2(1H)-pyridinone
• 英文别名: 3-benzyloxy-1-(succinimido-oxycarbonylmethyl)-pyrid-2-one；3-(benzyloxy)-1-{[(succinimidyloxy)carbonyl]methyl}-2(1H)-pyridinone；3-Benzyloxy-1-(succinimidooxycarbonylmethyl)-pyrid-2-one；(2,5-dioxopyrrolidin-1-yl) 2-(2-oxo-3-phenylmethoxypyridin-1-yl)acetate
• CAS: 95215-73-9
• 化学式: C₁₈H₁₆N₂O₆
• 分子量: 356.335
• InChiKey: JCMJUKQJBYQYMZ-UHFFFAOYSA-N

物化性质

• 熔点：
  174.5-175.0 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  602.8±65.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  93.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-(benzyloxy)-1-<<(succinimidyloxy)carbonyl>methyl>-2(1H)-pyridinone 在 palladium on activated charcoal 氢气 、 溶剂黄146 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 25.0h， 生成 2-(3-Hydroxy-2-oxo-2H-pyridin-1-yl)-N-isopropyl-acetamide
  参考文献：
  名称：

  新型3-羟基-2（1H）-吡啶酮。合成，铁（III）螯合性能和生物活性。

  摘要：

  描述了一系列包含螯合部分3-羟基-2（1H）-吡啶酮的新颖的二齿和六齿配体的合成。已经确定了配体的pKa值及其铁（III）配合物的稳定性常数。六齿配体之一的铁（III）配合物的稳定性常数与去铁胺B相当。配体及其铁（III）配合物的分布系数也被确定。新型六齿化合物之一已显示出可显着增强肝细胞和铁超载小鼠的铁（III）排泄。

  DOI：

  10.1021/jm00168a033
• 作为产物：
  描述：

  氯化苄 在 sodium hydroxide 、 N,N'-二环己基碳二亚胺 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 3-(benzyloxy)-1-<<(succinimidyloxy)carbonyl>methyl>-2(1H)-pyridinone
  参考文献：
  名称：

  新型3-羟基-2（1H）-吡啶酮。合成，铁（III）螯合性能和生物活性。

  摘要：

  描述了一系列包含螯合部分3-羟基-2（1H）-吡啶酮的新颖的二齿和六齿配体的合成。已经确定了配体的pKa值及其铁（III）配合物的稳定性常数。六齿配体之一的铁（III）配合物的稳定性常数与去铁胺B相当。配体及其铁（III）配合物的分布系数也被确定。新型六齿化合物之一已显示出可显着增强肝细胞和铁超载小鼠的铁（III）排泄。

  DOI：

  10.1021/jm00168a033

文献信息

• Pharmaceutical compositions
  申请人：National Research Development Corp.

  公开号：US04585780A1

  公开（公告）日：1986-04-29

  Pharmaceutical compositions containing a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionizable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by aliphatic hydrocarbon groups, or a salt thereof containing a physiologically acceptable ion or ions, are of value for removing toxic amounts of metals, particularly iron, from the body.

  含有3-羟基吡啶-2-酮或3-羟基吡啶-4-酮的药物组合物，其中连接到氮原子的氢原子被脂肪酰基、脂肪烃基或被脂肪烃基取代，并且被脂肪酰基、烷氧基、脂肪胺基、脂肪酰胺基、羧基、脂肪酯基、卤素、羟基和磺酸基中的一个或一个以上的取代基取代，除非是可电离的基团，可选地，其中连接到环碳原子的一个或多个氢原子被上述取代基之一取代，或者被烷氧基、脂肪酯基、卤素或羟基取代的脂肪烃基取代，但不包括化合物，其中所述取代氢原子的取代仅由脂肪烃基完成，或者其盐，含有生理上可接受的离子，对于从体内去除有毒金属，特别是铁，具有价值。
• Iron-pyridone complexes for anemia
  申请人：National Research Development Corporation

  公开号：US04650793A1

  公开（公告）日：1987-03-17

  Pharmaceutical compositions containing an iron complex of a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionizable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by aliphatic hydrocarbon groups, are of value for the treatment of iron deficiency anemia.

  含有3-羟基吡啶-2-酮或3-羟基吡啶-4-酮的铁络合物的药物组合物，其中氮原子上连接的氢原子被取代为脂肪族酰基团、脂肪族碳氢基团或被选自脂肪族酰基、烷氧基、脂肪族胺、脂肪族酰胺、羧基、脂肪族酯、卤素、羟基和磺酸基中的一个或一个以上取代基的烷基碳氢基团取代，且可选地，其中一个或多个连接到环碳原子的氢原子被取代为上述取代基之一，或被取代为烷氧基、脂肪族酯、卤素或羟基的脂肪族碳氢基团或被取代为烷氧基、脂肪族酯、卤素或羟基的脂肪族碳氢基团取代，但不包括仅由脂肪族碳氢基团取代化合物的价值，用于治疗缺铁性贫血。
• METALLOPROTEIN INHIBITORS
  申请人：Puerta T. David

  公开号：US20070117848A1

  公开（公告）日：2007-05-24

  The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R 1 , R 2 , R 3 , and R 4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.

  本发明涉及金属蛋白酶抑制剂，包括：a. 有机取代基和至少一个锌结合基团（ZBG）共价连接在一起；或者b. 通过侧链取代的ZBG，其中ZBG的公式为（I）：其中X为O或S，每个R1、R2、R3和R4分别为氢或有机基团。这些金属蛋白酶抑制剂可用于预防或治疗与病理性金属蛋白酶活性相关的病理性疾病、状况或症状，或者通过抑制该活性缓解的病理性疾病、状况或症状。
• Metalloprotein inhibitors
  申请人：The Regents of The University of California

  公开号：US07786316B2

  公开（公告）日：2010-08-31

  The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.

  本发明涉及金属蛋白酶抑制剂，包括：a. 有机取代基和至少一个与其共价连接的锌结合基（ZBG）；或b. 通过侧链取代的ZBG，其中ZBG的化学式为（I）：其中X为O或S，每个R1、R2、R3和R4分别为氢或有机基团。这些金属蛋白酶抑制剂可用于预防或治疗与病理金属蛋白酶活性相关的病理性疾病、病况或症状，并且通过抑制该活性可缓解该病理性疾病、病况或症状。
• Iron III complexes of hydroxypyridones, and their pharmaceutical compositions
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0120670A1

  公开（公告）日：1984-10-03

  Pharmaceutical compositions containing an iron complex of a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionisable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by aliphatic hydrocarbon groups, are of value for the treatment of iron deficiency anaemia.

  含有 3-羟基吡啶-2-酮或 3-羟基吡啶-4-酮铁络合物的药物组合物，其中与氮原子相连的氢原子被脂肪族酰基、脂肪族烃基或被一个或一个以上取代基取代的脂肪族烃基所取代（可电离基团除外），取代基选自脂肪族酰基、烷氧基、脂肪族胺、脂肪族酰胺、羧基、脂肪族酯、卤素、在可离子化基团的情况下，一个以上选自脂肪族酰基、烷氧基、脂肪族酰胺、羧基、脂肪族酯、卤素、羟基和磺基的取代基，以及环碳原子上的一个或多个氢原子被上述取代基、脂肪族烃基或被烷氧基、脂肪族酯、卤素或羟基取代的脂肪族烃基取代，但不包括化合物中的氢原子仅被脂肪族烃基取代的化合物，这些化合物具有治疗缺铁性贫血的价值。